Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $52.50, for a total value of $656,250.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
C Frank Bennett also recently made the following trade(s):
- On Tuesday, January 16th, C Frank Bennett sold 2,696 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.76, for a total value of $139,544.96.
Ionis Pharmaceuticals Inc (IONS) opened at $51.11 on Friday. Ionis Pharmaceuticals Inc has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The stock has a market capitalization of $6,170.00, a PE ratio of 365.07 and a beta of 2.53.
IONS has been the topic of several research reports. Stifel Nicolaus restated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target on the stock in a research note on Friday, October 27th. Morgan Stanley raised their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $50.76.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/02/03/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-12500-shares-of-stock.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.